This is a great article that explains ACAD and Why It will be going Alot Higher:
Seeking Alpha By: Scott Matusow
Acadia has drug candidates for the treatment of Parkinson's disease, Alzheimer's, schizophrenia, and glaucoma. These conditions are all connected with large market size and present significant opportunities for big pharma. Acadia has shown ability in the past to partner or collaborate with larger companies such as \Biovail, Allergan, and Meija Seika Kaisha, LTD. It is not being overly presumptive to assume that big pharma would have interest in Acadia for its lead drug pimavanserin, which possesses potential for massive revenue in multiple applications.
LMFAO....Seeking Alpha noobs? Keep pumping this #$%$. The new institutional owners will use that to make money shorting when retailers throw money at this on hopes of Bazzillions of dollars in years to come.....Oh what? you dont think institutions short stock? They are here for one thing: to make money.
SA articles are nothing to base your purchases off of... See Matusows article recommending ETRM be purchased in mid 3's, followed by its tanking to 0.8 after failing to meet primary endpoints not long after...